Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Huntsman Cancer Institute, Salt Lake City, Utah, United States

Survival: 8.0 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Gemzar
Country: United States
City/State/Province: Salt Lake City, Utah
Hospital: Huntsman Cancer Institute
Journal: Link
Date: 7/2006

Patients: This Phase II study involved 39 patients with previously untreated stage IIIB-IV non-small cell lung cancer with a median age of 66, ranging from 44-86. Twenty-three were men, 16 were women.

Treatment: The treatment consisted of the chemotherapeutic agents gemcitabine paclitaxel.

Toxicity: Grade 4 toxicities were neutropenia and pulmonary. Grade 3-4 neutropenia occurred in 20.5% of patients. Non-hematological toxicities of Grade 3-4 occurred in less than 10% of cases, except for pulmonary (which occurred in 10.2%).

Results: There was a high-dropout rate of patients during the first 8 weeks of therapy; contributing factors were poor performance, comorbidity, toxicity. Median overall survival was 32 weeks (7.4 months). The median progression free survival was 11.8 weeks. No complete responses were observed.

Support: This study was supported in part by grants from Lilly Oncology and Bristol-Myers Squibb. Eli Lilly manufactures and markets gemcitabine.

Correspondence: Wallace Akerley, M.D.

E-mail to a Friend Email Physician More Information